This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
S Alwan , J Reefhuis , SA Rasmussen , RS Olney , JM Friedman (2007). Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. New England Journal of Medicine 356, 2684–2692.
SE Andrade , H McPhillips , D Loren , MA Raebel , K Lane , J Livingston , DM Boudreau , DH Smith , RL Davis , ME Willy , R Platt (2009). Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 18, 246–252.
B Bar-Oz , T Einarson , A Einarson , R Boskovic , L O'Brien , H Malm , A Berard , G Koren (2007). Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clinical Therapeutics 29, 918–926.
A Bérard , E Ramos , E Rey , L Blais , M St-Andre , D Oraichi (2007). First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 80, 18–27.
CD Chambers , S Hernandez-Diaz , LJ Van Marter , MM Werler , C Louik , KL Jones , AA Mitchell (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine 354, 579–587.
TK Chung , TK Lau , AS Yip , HF Chiu , DT Lee (2001). Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosomatic Medicine 63, 830–834.
JA Cole , SA Ephross , IS Cosmatos , AM Walker (2007). Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiology and Drug Safety 16, 1075–1085.
AM Costei , E Kozer , T Ho , S Ito , G Koren (2002). Perinatal outcome following third trimester exposure to paroxetine. Archives of Pediatrics and Adolescent Medicine 156, 1129–1132.
RL Davis , D Rubanowice , H McPhillips , MA Raebel , SE Andrade , D Smith , MU Yood , R Platt (2007). Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiology and Drug Safety 16, 1086–1094.
J Dayan , C Creveuil , M Herlicoviez , C Herbel , E Baranger , C Savoye , A Thouin (2002). Role of anxiety and depression in the onset of spontaneous preterm labor. American Journal of Epidemiology 155, 293–301.
J Dayan , C Creveuil , MN Marks , S Conroy , M Herlicoviez , M Dreyfus , S Tordjman (2006). Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosomatic Medicine 68, 938–946.
G Dubnov-Raz , DN Juurlink , R Fogelman , P Merlob , S Ito , G Koren , Y Finkelstein (2008). Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 122, e710–e715.
TR Einarson , A Einarson (2005). Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiology and Drug Safety 14, 823–827.
A Ericson , B Källén , B Wiholm (1999). Delivery outcome after the use of antidepressants in early pregnancy. European Journal of Clinical Pharmacology 55, 503–508.
P Hallberg , V Sjöblom (2005). The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. Journal of Clinical Psychopharmacology 25, 59–73.
RN Hines , J Adams , GM Buck , W Faber , JF Holson , SW Jacobson , M Keszler , K McMartin , RT Segraves , LT Singer , IG Sipes , PL Williams (2004). NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 71, 193–280.
B Källén (1995). A birth weight for gestational age standard based on data in the Swedish Medical Birth Registry, 1985–1989. European Journal of Epidemiology 11, 601–606.
B Källén (2004). Neonate characteristics after maternal use of antidepressants in late pregnancy. Archives of Pediatrics and Adolescent Medicine 158, 312–316.
B Källén (2005). Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenital Anomalies 45, 44–51.
B Källén (2007). The safety of antidepressant drugs during pregnancy. Expert Opinion on Drug Safety 6, 357–370.
B Källén , P Otterblad Olausson (2003). Maternal drug use in early pregnancy and infant cardiovascular defect. Reproductive Toxicology 17, 255–261.
B Källén , P Otterblad Olausson (2006). Antidepressant drugs during pregnancy and infant congenital heart defect. Reproductive Toxicology 21, 221–222.
B Källén , P Otterblad Olausson (2007). Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Research. Part A, Clinical and Molecular Teratology 79, 301–308.
B Källén , P Otterblad Olausson (2008). Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 17, 801–806.
R Levinson-Castiel , P Merlob , N Linder , L Sirota , G Klinger (2006). Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Archives of Pediatrics and Adolescent Medicine 160, 173–176.
D Li , L Liu , R Odouli (2009). Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Human Reproduction 24, 146–153.
C Louik , AE Lin , MM Werler , S Hernandez-Diaz , AA Mitchell (2007). First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New England Journal of Medicine 356, 2675–2683.
N Lund , LH Pedersen , TB Henriksen (2009). Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Archives of Pediatrics and Adolescent Medicine 163, 949–954.
H Malm , T Klaukka , PJ Neuvonen (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics and Gynecology 106, 1289–1296.
PR McElhatton , HM Garbis , E Elefant , T Vial , B Bellemin , P Mastroiacovo , J Arnon , E Rodriguez-Pinilla , C Schaefer , T Pexieder , P Merlob , S Dal Verme (1996). The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reproductive Toxicology 10, 285–294.
TF Oberlander , W Warburton , S Misri , J Aghajanian , C Hertzman (2006). Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Archives of General Psychiatry 63, 898–906.
TF Oberlander , W Warburton , S Misri , J Aghajanian , C Hertzman (2008 a). Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. British Journal of Psychiatry 192, 338–343.
TF Oberlander , W Warburton , S Misri , W Riggs , J Aghajanian , C Hertzman (2008 b). Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 83, 68–76.
ST Orr , SA James , C Blackmore Prince (2002). Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. American Journal of Epidemiology 156, 797–802.
LH Pedersen , TB Henriksen , M Vestergaard , J Olsen , BH Bech (2009). Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. British Medical Journal 339, b3569.
AL Potts , KL Young , BS Carter , JP Shenai (2007). Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram. Journal of Perinatology 27, 120–122.
EJ Sanz , C De-las-Cuevas , A Kiuru , A Bate , R Edwards (2005). Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365, 482–487.
GE Simon , ML Cunningham , RL Davis (2002). Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry 159, 2055–2061.
JA Stiskal , N Kulin , G Koren , T Ho , S Ito (2001). Neonatal paroxetine withdrawal syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition 84, F134–F135.
R Suri , L Altshuler , G Hellemann , VK Burt , A Aquino , J Mintz (2007). Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. American Journal of Psychiatry 164, 1206–1213.
S Toh , AA Mitchell , C Louik , MM Werler , CD Chambers , S Hernandez-Diaz (2009). Selective serotonin reuptake inhibitor use and risk of gestational hypertension. American Journal of Psychiatry 166, 320–328.
M Treichel , K Schwendener Scholl , U Kessler , A Joeris , M Nelle (2009). Is there a correlation between venlafaxine therapy during pregnancy and a higher incidence of necrotizing enterocolitis? World Journal of Pediatrics 5, 65–67.
CL Wichman , KM Moore , TR Lang , JL St Sauver , RH Heise Jr., WJ Watson (2009). Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clinic Proceedings 84, 23–27.
KL Wisner , DK Sit , BH Hanusa , EL Moses-Kolko , DL Bogen , DF Hunker , JM Perel , S Jones-Ivy , LM Bodnar , LT Singer (2009). Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. American Journal of Psychiatry 166, 557–566.
P Wogelius , M Norgaard , M Gislum , L Pedersen , E Munk , PB Mortensen , L Lipworth , HT Sorensen (2006). Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17, 701–704.